Skip to main content

News

All the latest news and information on the main advances in research, institutional milestones, teaching and management. Find out what happens at the Vall d'Hebron Research Institute!

This pathology, common among patients who have undergone rectal resection due to cancer, causes alterations in bowel function with great impact on quality of life.

The money will allow research into paediatric nervous system tumours and childhood sarcomas to continue, with the aim of improving children's chances of survival and reducing the side effects of treatment.

This work sets the basis for future research aimed at a deeper understanding of the microbiota and the effect of nutrition.

The program is aimed at health innovation entrepreneurs and professionals interested in expanding their knowledge in the generation of innovative ideas, the search for unmet clinical needs, the development of medical technologies, finance, etc.

The project, which has received funding from the Association for Genetic Kidney Disease Information and Research, aims to help develop new therapies for familial hypomagnesemia with hypercalciuria and nephrocalcinosis.

Extracorporeal membrane oxygenation (ECMO) replaces lung function and therefore allows patients to be active even if their lungs are not functioning.

The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.

The association supports the Kidney Pathophysiology group at VHIR since 2015 to investigate familial hypomagnesemia with hypercalciuria and nephrocalcinosis.

The association makes the fifth annual donation of 52,390€ that will finance a project to study new therapies for this childhood tumor.

The team will design and implement a training program for professionals for the respectful care of maternity and childbirth.

The initiative, carried out at the Consulate of Bolivia, has resulted in 307 new tests for the diagnosis of Chagas disease

The new diagnostic method, designed for use in endemic regions, combines a mobile application with a low-cost robotic microscope.

On January 24, a session was held to explain what these three-dimensional models are and what advantages they have, as well as to review some of their applications in research.

CERTERA's objective is to create a coordinated research and innovation structure to accelerate the preclinical and early stage clinical development of these types of therapies.

Funding is key to bringing the neuroprotective drug ApTOLL to market and providing a new therapeutic option for the patients.

More than 400 students interested in acquiring knowledge and skills that will allow them to dedicate themselves to research aimed at finding solutions to people's health problems have already passed through the Master.

The BEACON clinical trial, in which Vall d'Hebron participates, has observed that adding Bevacizumab to treatment with different chemotherapy drugs reduces tumor size in a greater number of patients.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Phase IV AI is included in the Horizon Europe programme, lasts 3 years and prioritises data security and privacy compliance.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

These are the results of a study published in Nature Communications and led by the Vall d'Hebron Research Institute (VHIR), the University of Lleida (UdL) and the Biomedical Research Institute of Lleida (IRBLleida).

One study will improve the transition process of adolescents and, the other, will detect the risk of deterioration in hospitalised patients.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

The meeting, held between November 29 and December 2 in Barcelona, brought together experts and opinion leaders in the field of multiple sclerosis from around the world.